MyDrHank Review – Transparent on Price, Borrowed on Evidence

MyDrHank is a US telehealth platform that began in men's sexual health and now offers compounded GLP-1 weight loss alongside longevity, hair-loss and recovery products. On the things most providers hide, it does well: it publishes every price — compounded semaglutide from $178 a month, oral semaglutide from $171 and compounded tirzepatide from $240 — with free consultations, free delivery and unlimited messaging with a care team, and it states plainly that its compounded medications are not FDA-approved. Then it undercuts that with a headline efficacy claim taken from trials of a product it does not sell.

Overview

MyDrHank runs a standard telehealth flow: online case review by US-licensed providers, discreet home delivery, ongoing support with dose adjustments and unlimited care-team messaging. Its broader catalogue spans sexual health (sildenafil, tadalafil), longevity products (NAD+ and glutathione nasal sprays and injections), hair loss (minoxidil, finasteride) and sermorelin.

As with other providers of this shape, the adjacent categories carry considerably weaker evidence than the GLP-1 line. NAD+, glutathione and sermorelin for longevity and recovery are off-label uses with limited human data. If you are here for weight loss, there is no good reason to add them.

MyDrHank at a Glance

Pricing

Publishing three distinct prices with formats attached is better than most of this market manages, and free consultations plus free delivery mean the medication price is close to the all-in cost. The level is mid-market: above Trimi Health at $99, comparable to TrimRx at $179, below SkinnyRx at $249.

What is not published is whether these prices hold as your dose rises, or what the cancellation and refund terms are. Both are worth settling in writing before you enrol.

The 20.9% Claim Is Not About This Product

This is not a technicality we have invented. In March 2026 the FDA issued warning letters to around 30 telehealth companies specifically over marketing that implies compounded products share the evidence or approval status of branded ones. Our MEDVi review quotes one such letter, in which the agency stated that comparison claims "imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not". Our Strut Health review covers another from the same sweep.

What makes it particularly awkward here is that MyDrHank also states, correctly and prominently, that its compounded medications are not FDA-approved and that results with compounded formulations may differ. Both statements sit on the same service. The disclaimer is right; the headline undercuts it, and the headline is what a shopper reads first.

Our compounded vs brand-name guide sets out what actually differs — formulation, concentration, excipients, sterility assurance and stability, none of which transfer with the active ingredient.

Eligibility, Contraindications, and Side Effects

MyDrHank requires a prescription from a licensed US provider but does not publish eligibility criteria or the states it serves — a notable gap, since state licensure governs all telehealth prescribing. Confirm your state before paying. See our eligibility guide.

Semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumours, based on rodent studies. You should not take these medications if you or a family member have had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2, or if you have had a serious hypersensitivity reaction to the active ingredient. They are not for use in pregnancy. A history of pancreatitis, gallbladder disease, gastroparesis or other severe gastrointestinal disease, or diabetic retinopathy, warrants specific discussion first.

Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and abdominal pain — worst after a dose increase. Serious but less common risks include pancreatitis, gallbladder disease and acute kidney injury from dehydration. The oral option does not avoid them, and compounded oral semaglutide absorption is not established. Our side effects guide covers management; the unlimited care-team messaging is a genuine asset here.

How MyDrHank Compares

MyDrHank undercuts TrimRx on tirzepatide by more than $100 and is close on the oral option. Trimi is cheaper still and publishes its state coverage and pharmacies. On price alone MyDrHank is competitive; it is the evidence claim and the missing disclosures that hold it back.

Pros and Cons

Who Should Pick It, and Who Should Look Elsewhere

MyDrHank could suit you if you want compounded tirzepatide at a keen price with consultations and delivery included, and you are able to read past the marketing to the disclaimer underneath — which the company does provide. Publishing separate oral and injectable prices is genuinely helpful.

Look elsewhere if you want to know which states are served or what the cancellation terms are, neither of which is published. Trimi Health is cheaper on both drugs and publishes both. And if a provider quoting someone else's trial results for its own product troubles you, that is a reasonable place to draw the line.

Limitations of This Review

This review is based on MyDrHank's own site, checked on 7 August 2026. We found essentially no independent review record — no substantive Trustpilot or BBB data — so we cannot assess service quality, shipping reliability or how disputes are handled. State coverage, cancellation and refund terms are not published, and we could not identify the compounding pharmacy or verify the LegitScript status. We have not signed up, been prescribed, or received medication.

Frequently Asked Questions

Verdict

There is a reasonable service here. Three prices published with formats attached, free consults, free delivery, unlimited messaging and a correct statement of the compounded regulatory position put MyDrHank ahead of several better-known competitors on transparency. But it then leads with "up to 20.9% body weight loss in clinical trials" for a compounded product that has never been in a trial — the exact conflation the FDA has been writing to this industry about all year. Add undisclosed state coverage and no review record, and it is hard to place much weight on what it says about itself.